Last week, the FDA announced a recall on 32-milligram single intravenous (IV) doses of Zofran because of the potential for serious cardiac risks.
What is the problem with this anti-nausea drug that has brought about relief for so many? The FDA says Zofran can cause an irregular heart rhythm called prolonged QT interval when taken in such high doses. This condition can result in a potentially fatal rhythm problem known as Torsades de Pointes, an uncommon and distinctive form of polymorphic ventricular tachycardia.
Back in June, GlaxoSmithKline released a study that led them to instantly update their warning to warn of the risk of heart arrhythmias. At that time, Glaxo removed 32-mg single doses from the drug’s label.
Ultimately, this is not a case where the drug companies are making tons of money from these 32-milligram IV doses of Zofran. It makes up a fraction of a fraction of their huge profits on Zofran. But it was made available in high does for people who had awful issues with nausea, many of which are undergoing chemotherapy and are near death. I’m sure some argue that doctors should be able to make the call on the cost benefit of this high dose of Zofran.
My whole point is this: I’m a plaintiff’s lawyer. We are looking for new clients in many different types of drug injury cases. And we are not looking at Zofran lawsuits. Mileage may vary. So don’t take my word for it. There are lawyers out there marketing for these cases already.
Disclaimer: I have used Zofran, and I think it is a miracle drug.